Novel biologically based therapies targeting MM cells and the BM microenvironment. Novel agents (A) induce G1 growth arrest and/or apoptosis in MM cell lines and patient cells resistant to conventional chemotherapy; (B) inhibit MM cell adhesion to BMSCs; (C) decrease cytokine production and sequelae in the BM microenvironment; and (D) decrease angiogenesis.